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Populations in North Africa (NA) are characterized by a high rate of consanguinity. 
Consequently, the proportion of founder mutations might be higher than expected and 
could be a major cause for the high prevalence of recessive genetic disorders like Fanconi 
anemia (FA). We report clinical, cytogenetic, and molecular characterization of FANCA in 
29 North African FA patients from Tunisia, Libya, and Algeria. Cytogenetic tests revealed 
high rates of spontaneous chromosome breakages for all patients except two of them. 
FANCA molecular analysis was performed using three different molecular approaches 
which allowed us to identify causal mutations as homozygous or compound heterozygous 
forms. It included a nonsense mutation (c.2749C > T; p.Arg917Ter), one reported missense 
mutation (c.1304G > A; p.Arg435His), a novel missense variant (c.1258G > A; p.Asp409Glu), 
and the FANCA most common reported mutation (c.3788_3790delTCT; p.Phe1263del). 
Furthermore, three founder mutations were identified in 86.7% of the 22 Tunisian patients: 
(1) a deletion of exon 15, in 36.4% patients (8/22); (2), a deletion of exons 4 and 5 in 23% 
(5/22) and (3) an intronic mutation c.2222 + 166G > A, in 27.3% (6/22). Despite the relatively 
small number of patients studied, our results depict the mutational landscape of FA among 
NA populations and it should be taken into consideration for appropriate genetic counseling.
Keywords: consanguinity, founder mutations, North Africa, molecular diagnosis, Fanconi anemia, FANCA
INTRODUCTION
Fanconi Anemia (FA) is a rare, inherited disorder clinically characterized by various congenital 
abnormalities and a predisposition to develop malignancies, especially acute myeloid leukemia, 
and other cancers (Kutler et al., 2003). The prognosis of the disease is characterized by an evolution 
toward progressive bone marrow failure (BMF). Without treatment, FA is most often lethal before 
the end of the second decade of life. Cells from FA patients present high levels of spontaneous 
chromosomal breakages (Schroeder and Kurth, 1971) that increase dramatically by clastogens such 
as Mitomycin C (MMC; Cervenka et  al., 1981) and Diepoxybutane (DEB; Auerbach, 2009).
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FA is genetically heterogeneous, with at least 22 genes 
encoding for a group of proteins that cooperate in a unique 
FA/BRCA DNA repair pathway (Nalepa and Clapp, 2018). 
Indeed, the products of these genes are involved in the 
preservation of genome integrity in response to physiological 
stress or to genotoxic agents (Kottemann and Smogorzewska, 
2013; Ceccaldi et  al., 2016). All FA genes are located on 
autosomal chromosomes except FANCB which is X-linked 
(Kitao and Takata, 2011). FANCA, FANCC, and FANCG 
complementation groups include, respectively, 60, 15, and 10% 
of all FA patients from the USA, whereas mutations in other 
FA genes occur less frequently (<1–4%; Neveling et  al., 2009).
Several reports indicated a higher FA prevalence in some 
ethnic groups like the Spanish Romani (Callén et  al., 2005; 
Castella et al., 2011), the Afrikaner population of South Africa 
(Tipping et al., 2001), Ashkenazi Jewish (Whitney et al., 1993), 
and Tunisian populations (Amouri et al., 2014) due to founder 
effects and isolation. Thus, information on a patient’s ethnic 
origin may provide evidence for a pathogenic mutation that 
is likely to be  causal (Faivre et  al., 2000; Tipping et  al., 2001; 
Kutler and Auerbach, 2004; Castella et  al., 2011). In Tunisia, 
FA-A complementation group is the most prevalent, with a 
94% frequency among the FA patients (Bouchlaka et  al., 
2003). A common haplotype shared by FA patients mostly 
originating from the South of Tunisia was associated with 
the deletion of exon 15  in FANCA (Bouchlaka et  al., 2003; 
Amouri et  al., 2014). Another founder mutation in the same 
gene (c.890_893del in exon 10) was identified in Tunisian 
Jewish FA patients (Tamary et  al., 2000). In neighboring 
countries, Algeria and Libya, no FA molecular studies have 
been conducted so far. However, several studies on other 
genetic conditions have shown that patients originating from 
North Africa (NA) shared many common founder mutations 
(Richard et al., 2008; Messaoud et al., 2010; Bensenouci et al., 
2016). According to more than 20  years’ experience on the 
investigation of genetic diseases, identification of founder 
mutations that are shared between Tunisia and other NA 
countries even with a single patient were of great impact 
for launching molecular diagnosis in their respective countries. 
This was the case for Xeroderma pigmentosum (Senhaji et  al., 
2013) and for several other diseases (Romdhane et  al., 2012; 
Charoute et  al., 2015).
The present study aims to investigate the FANCA mutational 
spectrum and to develop a strategy based on molecular 
approaches applicable to routine clinical use for FA patients 
originating from NA.
MATERIALS AND METHODS
A total of 87 families with 113 FA patients have been addressed 
to our department in Institut Pasteur de Tunis (IPT) for 
confirmation of FA based on the standard test involving 
MMC-induced chromosomal breakage analysis. The cytogenetic 
and molecular status of 30 families with 46 patients have been 
previously described (Talmoudi et al., 2013; Amouri et al., 2014). 
Since FA is a rare disease, it was difficult to recruit a large 
number of patients. Under these circumstances, the conduct, 
the analysis and the interpretation of studies on this disease 
may sometimes be limited to different degrees by its prevalence. 
Also, we  have to take into consideration the severe health 
status of the patients in particular in regard to their extremely 
severe anemia, especially that we give the priority to diagnosis 
(cytogenetic study), thus most of the patients were investigated 
cytogenetically but no sufficient material was available to 
conduct molecular investigation. Furthermore, most of the 
cases are pediatric cases and we  try to avoid any invasive 
tests including recurrent blood sampling. Therefore, we  were 
not able to collect additional samples for DNA investigation. 
Finally, transplanted and recently transfused patients were 
excluded from the study. As a direct outcome of these, the 
present study was conducted on 22 newly collected families, 
including 29 FA patients who agreed to participate in the 
molecular genetic testing.
This study was conducted according to the principles of 
the Declaration of Helsinki and was approved by the biomedical 
ethics committee (2017/14/I/LR11IPT05/V0) of Pasteur Institute. 
Informed consent of the legal patients’ representatives were 
obtained. Peripheral blood samples were collected from the 
29 FA patients, their parents, and their siblings when available.
Genomic DNA was extracted using the standard salting-out 
method (Miller et  al., 1988) or the QIAamp DNA mini kit 
(Qiagen).
Clinical examination and familial information details were 
recorded. Clinical data were obtained based on history, physical 
examinations, and reviewing of medical records.
Patients were initially screened using PCR to check the 
homozygous deletion of the exon 15  in the FANCA gene 
(LRG_495) which is a common founder mutation in Southern 
Tunisia (Amouri et  al., 2014).
The 43 coding exons of FANCA gene were amplified using 
PCR. Intronic oligonucleotides primer pairs were generated 
using Primer 31 and in silico PCR (UCSC).2 Direct sequencing 
of PCR products was performed on an ABI prism 3,500 DNA 
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), 
using the ABI Prism Big Dye Terminator v3.1 Cycle Sequencing 
Ready Reaction Kit (Applied Biosystems). Sequences were then 
analyzed using Bioedit software and compared to the wild 
sequence using BLAST program available in the NCBI server.
Multiplex ligation-dependent probe amplification (MLPA) 
was performed to detect large deletions or duplications within 
the FANCA gene using a SALSA P031-A2/P032 kit (MRC-Holland 
BV, Amsterdam, The Netherlands) for (F068/15, TFA27, SFA15, 
F076/15, F031/15, F032/15, and F050/15) patients. PCR products 
were analyzed using ABI PRISM 3130 Genetic analyzer 
(Applied Biosystems).
For (TFA27, SFA15, F059/15, F058/15, CFA4, CFA3, 
F033/15, and TFA23) patients, available family members 
were genotyped with three microsatellites flanking the FANCA 
gene (D16S3026‐ D16S3121‐ D16S3407) as previously reported 
(Bouchlaka et  al., 2003).
1 http://primer3.ut.ee/
2 http://genome.ucsc.edu/cgi-bin/hgPcr
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Targeted gene sequencing (TGS) has been conducted for 
(F072/09, SFA2, GF06/09, and GF78/09) patients. Custom design 
of the genes’ panel was performed using SureDesign (Agilent 
Technologies Inc.); probes were generated to cover the exons 
and 15  bp of the surrounding intronic sequences of a total 
of 87 candidate genes known to be  involved in DNA repair 
disorders. Library preparation for NGS was performed using 
Agilent’s HaloPlexHS (high sensitivity) workflow as a target 
enrichment method. Amplicon libraries were prepared from 
patients’ genomic DNA using the HaloPlexHS PCR target 
enrichment system dedicated to Ion Torrent PGM according 
to the manufacturer’s recommendations. Massively parallel 
sequencing was performed on an Ion Torrent PGM (Thermo 
Fisher Scientific). In our analysis we  used the Ion Torrent 
Suite Software v.4 to process our data and we  configured the 
settings to reduce the total number of false positive indels 
caused by the high frequency of homopolymer sequencing 
errors (min_cov_each_strand: 0, min_variant_score: 10, min_
allele_freq: 0.1, snp_min_coverage: 6 snp and indel; strand_bias: 
0.98 snp and 0.85 indel). In addition, we  visually evaluated 
the read depth and the percentage of mutated reads for each 
variant using the Integrative Genomic Viewer (IGV). Finally, 
validation by MLPA was made to confirm the identified indels. 
Data were analyzed using the in-house VarAft software version 
2.5, which is available online.3 We  prioritized rare functional 
variants (missense, nonsense, splice site variants, and indels) 
and excluded variants with a Minor Allele Frequency 
(MAF) > 0.01  in dbSNP137 and 138, in the Exome Variant 
Server,4 1000 Genomes Project,5 or Exome Aggregation 
Consortium database (ExAC), Cambridge, MA.6 A number of 
online tools were used to predict the functional impact and 
pathogenicity of the variants such as MutationTaster,7 PolyPhen,8 
SIFT,9 I-mutant,10 and CADD.11
RESULTS
In this study, we  report on the clinical, cytogenetic, and 
molecular investigation of 22 families including 29 FA patients. 
Our cohort is composed of 8 girls and 21 boys (sex ratio = 2.625) 
aged from 1 to 28  years. Inbreeding examination showed that 
25 patients (86.20%) were born from consanguineous unions. 
Eight families are multiplex (having more than one affected 
child). Geographical distribution showed that five patients are 
from Libya, one from Algeria, one Algerian/Tunisian patient 
(father: from Algeria; mother: from Tunisia) and 22 are Tunisians. 










originating from Southern Tunisia, six from Central Tunisia 
and two from Northern Tunisia.
Most of patients presented typical clinical features of FA 
including: skin pigmentation abnormalities (86%), microcephaly 
(52%), triangular face (31%), and skeletal malformations (34%). 
Other clinical abnormalities, such as ear abnormalities and 
hearing problems were presented in two patients (F032/16 and 
F076/15).
Chromosomal breakage analysis was successful in all patients 
except for two patients (GF78/09 and SFA2), for whom blood 
cell culture showed no growth. For these two patients, results 
of the molecular analysis confirmed the FA diagnosis. For the 
others, cytogenetic results revealed a high frequency of 
chromosomal breakages (>3 breaks/cell in MMC treated, up 
to 0.2 breaks/cell in untreated) in 27 patients when compared 
to controls (0.1 break/cell in MMC treated, up to 0.03 breaks/
cell in untreated).
The molecular approach allowed us to identify seven different 
pathogenic variants at homozygous and heterozygous states. 
These variants include large deletions of one or two exons 
(deletion of exon 15, deletion of exons 4 and 5) respectively, 
one nonsense mutation (c.2749C > T; p.Arg917Ter) in exon 
28, a small deletion (c.3788_3790del; p.Phe1263del) in exon 
38, one likely pathogenic missense variant (c.1304G > A; 
p.Arg435His) in exon 14 that was already associated to FA 
(Moghrabi et al., 2009), a previously reported intronic mutation 
c.2222 + 166G > A (Bouchlaka et  al., 2003) in intron 24, and 
a novel missense variant of uncertain significance (c.1258G > A; 
p.Asp409Glu) in exon 14. For variant c.1258G > A; p.Asp409Glu, 
no functional study, nor cDNA analysis has been performed, 
however, the reported minor allele frequency (MAF) in GnomAD 
exomes (0.00000796) and GnomAD Genomes (0.0000319) and 
in silico evaluations with predictive algorithms (SIFT, 
POLYPHEN2, Align GVGD) indicate its possible pathogenicity.
The last intronic mutation was inherited at a homozygous 
state in all FA patients originating from Kairouan (Central 
Tunisia). Furthermore, all these patients shared the same 
haplotype (206-81-200; Figure  1).
All patients from Sidi Bouzid and Gafsa were homozygous 
for the founder mutation, deletion of exon 15, except for one 
patient originating from Gafsa (GF14/12) and another Libyan 
patient (F075/03) who were both homozygous for the novel 
missense variant c.1258G > A; p.Asp409Glu.
Haplotype findings showed that the patient (SFA15) shares 
the same homozygous haplotype described to be  associated 
with the founder deletion of exon 15  in Tunisian patients 
(Amouri et  al., 2014). On the other hand, the same haplotype 
was identified at a heterozygous state in the Algerian patient 
(TFA27) carrying the deletion in one allele. This patient is 
probably compound heterozygous. These results suggest a 
common ancestor between Tunisian, Libyan, and Algerian FA 
patients bearing the exon 15 deletion but do not exclude the 
hypothesis of another ancestor, especially for Algerians 
(Figure  2).
Deletion of exons 4 and 5 has been identified in five patients 
originating from Sfax. Four of them belong to two related 
families (family 10 and family 11) and were homozygous for 
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this large deletion. The other patient (GF06/09) was heterozygous 
and the second mutation is still unknown.
Our findings showed that deletion of exon 15, the large 
deletion of exons 4 and 5, and the intronic mutation 
c.2222 + 166G > A are founder mutations in Sidi Bouzid/Gafsa, 
Sfax, and Kairouan, respectively (Figure  3).
A summary of genealogical, clinical, cytogenetic, and molecular 
characteristics of the 29 studied patients is presented in Table 1.
FIGURE 1 | Pedigrees of FA nuclear families originating from Tunisian center (Kairouan) showing genotyping results of three microsatellites markers flanking FANCA 
gene. The presence of a common haplotype in all patients indicates a founder effect.
FIGURE 2 | Haplotype analysis for a Libyan SFA15 and an Algerian TFA27 patients. The Libyan patient SFA15 carries homozygously the founder haplotype (226-
95-218) already described among Tunisian patients as associated with exon 15 deletion. The Algerian patient TFA27 carries both the founder haplotype associated 
with exon 15 deletion in the heterozygous state and another haplotype (230-99-216).
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DISCUSSION
This study has been carried out with 29 FA patients. Their 
clinical features vary from one patient to another, but the 
common characteristics were: short stature, microcephaly, 
skin pigmentation, and skeletal abnormalities. Clinically, 
we  found that facial dysmorphia was a common feature in 
the majority of our patients. This could be  related to the 
predominance of the FANCA gene. Indeed, a correlation 
study between the phenotype of FA patients and the different 
complementation groups revealed a significantly higher 
frequency of facial dysmorphia in patients from groups A, 
G, and C (Faivre et  al., 2000). Similarly, congenital 
malformations (skeletal and skin) were observed in most 
patients. This is not surprising since a previous study conducted 
on patients with two founder mutations (deletion of exon 
15 and the intronic mutation) showed that malformations 
were present in 96% of cases and consisted mainly of skeletal 
malformations. Skin pigmentation abnormalities were present 
in 92% of cases (Bouchlaka et  al., 2003). In addition, an 
epidemio-clinical study carried out on Tunisian FA patients 
showed that skin, head, and skeletal abnormalities were 
common among these patients (90, 71, and 51%), respectively 
(Hadiji Mseddi et  al., 2012).
Clinical heterogeneity within the same family or between 
patients having the same mutation was also observed in our 
study. This could be  explained by environmental, genetic, and/
or epigenetic factors (Koc et  al., 1999). It should be  noted 
that there is little genotype–phenotype correlation, apart from 
the greater severity of group D2 and the association of groups 
D1/BRCA2 and N with the occurrence of multiple and very 
early cancers (Mialou, 2011).
In addition, a few previous publications have examined the 
correlations between the types of specific FANCA mutations 
and phenotype. In fact, a Spanish study showed that no 
association was found between the type of FANCA mutations 
and hematological diseases or somatic malformations (Castella 
et  al., 2011). The discrepancies observed between these studies 
may reflect specific characteristics of the population, making 
it difficult to rely on the Fanconi group or the type of mutation 
to define the risk of disease complications.
Our results at the clinical and cytogenetic level showed the 
absence of any correlation between the severity of the disease 
and the level of cellular sensitivity to MMC which fits with 
the observations reported in the literature (Castella et al., 2011; 
Zen et al., 2011; Talmoudi et al., 2013). Therefore, the cytogenetic 
approach can be  considered as an important diagnostic tool 
for aplastic anemia, especially for asymptomatic cases for whom 
A
B
FIGURE 3 | (A) Geographic distribution of mutations in the FANCA gene among Algerian and Libyan patients; (B) Geographic distribution of mutations in the 
FANCA gene including three founder mutations among Tunisian patients: c.2222 + 166G > A in Kairouan (Central Tunisia), deletion of exon 15 in Sidi Bouzid 
(Southern Tunisia) and Gafsa (Southern Tunisia), and deletion of exons 4 and 5 in Sfax (Southern Tunisia).
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Origin Clinical manifestations Percentage of 
chromosomal 
instability (CI %)
Type of mutations Zygosity Detection 
methods






‐Anomalies of the thumb
100%
(c.2749C > T; 
p.Arg917Ter) 
Deletion of exon 15
CH MLPA/DS
Family 2 TFA27 M/1 2nd degree Algeria
‐Microcephaly 
-Hyperpigmentation





‐Café au lait spots
100%





-An extra thumb 
-Café au lait spots
100%
(c.2749C > T; 
p.Arg917Ter)
Hz MLPA/DS




(c.1258G > A; 
p.(Asp409Glu))
Hm DS
Family 5 GF78/09 M/2 1st degree Libya
-Thrombocytopenia 
-Ecchymotic tasks 
‐A triangular facies 
-Red hair 
-Hypoplasia of the right thumb
No growth of  
blood cell culture
(c.1304G > A; 
p.Arg435His)
Hm TGS
Family 6 SFA15 M/11 2nd degree Libya
‐Microcephaly 
‐Thrombocytopenia 
‐Anomalies of the thumb




North of Tunisia 
(Mateur)







‐A triangular facies 
‐Café au lait spots
100%
Family 8 GF14/12 M/5 No
South of Tunisia 
(Gafsa)
‐Microcephaly 
‐Café au lait spots
100%
(c.1258G > A; 
p.(Asp409Glu))
Hm DS
Family 9 GF06/09 M/19 1st degree
South of Tunisia 
(Sfax)
-Facial dysmorphism 
-Café au lait spots
90%


















‐Anomalies of the thumb 
-Café au lait spots 
-Hyperpigmentation 
-Short stature




1st degree South of Tunisia 
(Sfax)







Deletions of exons 4 
and 5
Hm MLPA/DS




Family 12 F073/15 M/10 1st degree South of Tunisia 
(Gafsa)
-Triangular facies 
-Café au lait spots
100% Deletion of exon 15 Hm DS
Family 13 F022/17 M/10 1st degree




100% Deletion of exon 15 Hm DS
Family 14 F008/17 M/12 1st degree
South of Tunisia 
(Gafsa)
-Café au lait spots 
-Pre-axial polydactyly
100% Deletion of exon 15 Hm DS
(Continued)
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absence of clinical signs and any familial history would made 
the clinical diagnosis very challenging, hence showing the 
importance of chromosomal breakage assessment for the 
establishment of an accurate and rapid diagnosis. Indeed, testing 
for induced chromosomal breakage is commonly used for a 
precise diagnosis in the frame of a proper management of FA 
patients (bone marrow transplant) and their families (genetic 
counseling and prenatal diagnosis). Though molecular methods 
are developed to screen FA patients, cytogenetic investigations 
with MMC and DEB induction is still “the gold standard” for 
diagnosing FA.
As showed with previous reports, FANCA is the most frequent 
gene (94%) associated with FA in Tunisia (Bouchlaka et  al., 
2003). This result suggests that FANCA could be also the most 
causal gene of FA in other NA countries like Algeria and 
Libya considering their common genetic and 
historical background.
As previously shown, the deletion of exon 15 in the FANCA 
gene is a founder mutation present at a frequency of 54% 
among FA-A Tunisian patients (Amouri et  al., 2014). This 
deletion was found to be  the most frequent mutation in our 
cohort (11/29 patients: 37.93%). All the Tunisian patients bearing 
this deletion were from Sidi Bouzid and Gafsa. This is not 
surprising as we  have previously reported that the geographic 
distribution of 85% of families bearing this deletion are from 
Southern Tunisia thus suggesting a founder effect (Amouri 
et al., 2014). Furthermore, FA cases of Maghrebian origin living 
in France (Amouri et  al., 2014) and Spain (unpublished data) 
shared this deletion. Our findings, together with what 









Origin Clinical manifestations Percentage of 
chromosomal 
instability (CI %)



















-Café au lait spots
100%
Family 16 F025/17 F/9 1st degree
South of Tunisia 
(Sidi Bouzid)
-Triangular facies 
-Café au lait spots 
-Anomalies of the thumb








-Anomalies of the thumb
81%
Deletion of exon 15 Hm DS
F060/16 M/5






Center of Tunisia 
(Kairouan)
-Microcephaly 
-Café au lait spots 
-Anomalies of the thumb
85%
c.2222 + 166G > A Hm DS
F059/15 M/5
-Microcephaly 
-Café au lait spots 
‐Anomalies of the thumb
92%
Family 19 CFA4 M/6 1st degree
Center of Tunisia 
(Kairouan)
-Microcephaly 
-Café au lait spots
100% c.2222 + 166G > A Hm DS
Family 20 CFA3 M/4 1st degree
Center of Tunisia 
(Kairouan)
-Triangular facies 
-Café au lait spots
100% c.2222 + 166G > A Hm DS
Family 21 F033/15 M/3 1st degree
Center of Tunisia 
(Kairouan)
-Café au lait spots 100% c.2222 + 166G > A Hm DS
Family 22 TFA23 M/8 1st degree
Center of Tunisia 
(Kairouan)
-Microcephaly 
-Café au lait spots
100% c.2222 + 166G > A Hm DS
CH, compound heterozygous; Hm, homozygous; Hz, heterozygous; M, male; F, female; DS, direct sequencing; MLPA, multiplex ligation-dependent probe amplification; TGS: 
targeted gene sequencing.
References for described mutations:
 • Solanki et al., 2016: c.2749C > T; p.Arg917Ter
 • Amouri et al., 2014: Deletion of exon 15
 • Moghrabi et al., 2009: c.1304G > A; p.Arg435His
 • Magdalena et al., 2005: c.3788_3790delTCT
 • Ameziane et al., 2008: Deletion of exons 4 and 5
 • Bouchlaka et al., 2003: c.2222 + 166G > A
TABLE 1 | Continued
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deletion is the most common mutation among NA population 
and this observation has to be  taken into consideration mainly 
for migrated families. Similar findings have been observed in 
NA countries for several diseases. For instance, congenital 
myasthenic syndrome patients living in France and originating 
from Tunisia, Algeria, Morocco, and Libya share the same 
haplotype associated with the point founder mutation 
(c.1293insG) in CHRNE which has been also found in patients 
from the Maghreb (Richard et  al., 2008).
Another large deletion including exon 4 and 5 has been 
found in patients originating from Sfax (17%; Figure  4). This 
deletion was firstly described in two patients from Northwestern 
Europe in heterozygous states (Ameziane et  al., 2008). A 
molecular study applied for Spanish patients revealed the 
presence of this large deletion (Castella et  al., 2011). This 
mutation could probably be  introduced in Tunisia when 
Andalusians began crossing the strait of Gibraltar to seek refuge 
in NA in 1492 but a haplotype analysis should be  performed 
to confirm or discard this hypothesis.
Our results showed large intragenic deletions as the most 
frequent mutations found in homozygous and heterozygous 
states in 55.17% of the patients. This frequency is higher than 
that observed in other populations [31.25% in India (Solanki 
et  al., 2016); 25% in Brazilian patients (Pilonetto et  al., 2017)]. 
A meta-analysis has shown that between 15 and 40% of 
pathogenic mutations in FANCA are caused by large deletions 
(Ameziane et  al., 2012; Gille et  al., 2012). This is explained 
by the presence of a large number of Alu repeat sequences 
within FANCA (Levran et al., 1998; Morgan et al., 1999; Moghrabi 
et  al., 2009). Besides the genetic structure of the FANCA gene, 
the high frequency of deletions noted among NA population 
is likely resulting from the presence of founder mutations.
Screening by PCR and Sanger sequencing of FANCA 43 exons 
allowed the identification of 5 different nucleotide changes in 
14 FA cases (47%): one reported missense mutation (c.1304G>A; 
p.Arg435His), a novel missense variant (c.1258G > A; p.Asp409Glu), 
a nonsense mutation (c.2749C > T; p.Arg917Ter), a small deletion 
(c.3788-3790delTCT), and an intronic mutation (c.2222 + 166G>A). 
Some identified variants were described in other populations 
(Magdalena et  al., 2005; Moghrabi et  al., 2009; Solanki et  al., 
2016). However, none of them were described before in NA 
patients, except for the intronic mutation c.2222 + 166G > A 
(Bouchlaka et  al., 2003). This mutation inherited in all FA 
patients originating from Kairouan (central Tunisia) represents 
the second most frequent mutation in our cohort (20.68%). 
This pathogenic variant always segregates with the same haplotype, 
already described (Bouchlaka et  al., 2003). Our finding suggests 
that this intronic mutation has a common ancestor in Kairouan.
The identification of a founder mutation specific to a given 
geographic origin facilitates the diagnosis and reduces the 
diagnosis cost. In fact, various laboratories have adapted their 
strategies to optimize the chances of detecting the causal 
mutation while keeping costs to a minimum and decreasing 
the time required to get a reliable result.
The identification of a founder mutation specific to a given 
geographic origin facilitates the diagnosis and reduces the 
FIGURE 4 | CNV plots for patients (GF06/09 and F072/09) showing exon 4 and 5 deletion. The plots indicate a heterozygous deletion for patient GF06/09 while it 
is homozygous for patient F072/09. The two plots also show a decrease of the exon 1 signal but the quality control does not retain it as a deletion.
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diagnosis cost. Indeed, in Tunisia, among 174 genetic diseases 
with an identified molecular defect, 73 (41.9%) are due to 
founder mutations (Romdhane and Abdelhak, 2011; Elloumi 
Zghal and Chaabouni Bouhamed, 2018; Romdhane et al., 2019). 
This high frequency of founder mutations could be  explained 
by the high rates of inbreeding and endogamy that characterize 
NA populations: 34.04% in Algeria, 37.6% in Libya and 29.9% 
in Tunisia (Abudejaja et  al., 1987; Zaoui and Biémont, 2002; 
Ben Halim et al., 2013). The most frequent form of intermarriage 
is between first cousins, particularly paternal first cousins and 
includes double first-cousin marriage (Ben Halim et  al., 2013). 
Considering the first cousins’ marriages, the risk of recessive 
hereditary diseases is multiplied by an average of 8 times, 
which doubles the total frequency of congenital and genetic 
diseases (Romdhane et  al., 2014; Ben Halim et  al., 2016). In 
our study, 86% of our families are consanguineous (Figure  5), 
which may explain the elevated number of deleterious mutations 
found at a homozygous state in the affected patients (82.75%). 
Similar values between the consanguinity rate and the percentage 
of homozygous mutations clearly show the impact of inbreeding 
on the genomic structure by increasing the number of regions 
of homozygosity and hence homozygous pathogenic variants.
Some of the identified FANCA variants (Deletion of exon 
15; p.Arg917Ter; p.Arg409Glu) are shared among Tunisian, 
Libyan, and Algerian patients. These findings enhance the 
previous observations that NA patients share a common ethnic 
background and consequently the same mutational spectrum 
(Romdhane et  al., 2012).
NA is characterized by its mixed population history due to 
migratory/invasive flows which have resulted in high levels of 
genetic and phenotypic variability. Our results contain private 
mutations, ethnic specific mutations, and recurrent founder 
mutations, thus reflecting a great genetic heterogeneity of FANCA 
mutations within the NA population. Indeed, prioritizing mutation 
screening by relying on deleterious gene variants already identified 
in neighboring populations can be  particularly efficient. This 
was the case for the recurrent mutation p.V548AfsX25 affecting 
XPC and leading to Xeroderma pigmentosum. This mutation was 
firstly described in Algerian and Moroccan patients in a 
homozygous state (Khan et  al., 2006), then another study 
demonstrated its high prevalence in Tunisian patients and confirmed 
a founder effect in this population (Ben Rekaya et  al., 2009).
The molecular approach applied in this study allowed us to 
identify causative variants for almost all patients (25 
patients: 86.20%). However, the second mutated allele failed to 
be  identified for the rest of patients (four patients: 13.79%). 
Taking together, we can conclude that the combination between 
MLPA Sanger sequencing and, possibly, TGS methods for FANCA 
mutations screening seems to be  the appropriate molecular 
approach for a precise diagnosis of FA patients in NA (Figure 6). 
For patients (TFA27, GF06/09, F031/16 and F032/16) whose 
second mutated allele was not identified, it could be  explained 
by (i) the presence of a second undetected pathogenic variant 
in intronic or regulatory regions; (ii) another FA gene could 
be  mutated in TFA27, and the presence of FANCA exon 15 
deletion could be due to its higher prevalence in the NA population.
The assignment of NA patients to their genetic FA subtypes 
and the identification of their respective mutations provide 
valuable data for a better knowledge of the genetic basis of 
FA in NA and for a more appropriate management of patients 
at both preventive (plan for genetic counseling and prenatal 
diagnosis) and therapeutic (selection of suitable donors for 
hematopoietic stem cell transplantation) levels.
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